Last reviewed 2026-04-20 · How we verify

Incruse

At a glance

Approved indications

• Asthma
• Chronic bronchitis
• Chronic obstructive lung disease
• Pulmonary emphysema

Common side effects

• Nasopharyngitis
• Upper respiratory tract infection
• Cough
• Arthralgia
• Pharyngitis
• Viral upper respiratory tract infection
• Myalgia
• Abdominal pain upper
• Toothache
• Contusion
• Tachycardia
• Urinary tract infection

Serious adverse events

• Atrial fibrillation
• Supraventricular tachycardia
• Supraventricular extrasystoles
• Sinus tachycardia
• Idioventricular rhythm
• Pneumonia
• Depression
• Vertigo
• Diarrhea
• Rash

Key clinical trials

• Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
• VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
• Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study (PHASE4)
• Immuno-inflammatory Response of Erdosteine in COPD (NA)
• To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
• Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (PHASE4)
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
• 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.